Merck Invests In Pan-canadian Life Sciences Research Innovation Sector

Merck Invests In Pan-canadian Life Sciences Research Innovation Sector 
A $4-million public-private partnership will promote research innovation 
involving three academic commercialization centres in Canada 
CHICAGO, ILLINOIS, April 22, 2013 /CNW Telbec/ - Merck Canada will be 
announcing today at the BIO International Convention that it is reinforcing 
its commitment to the Canadian life sciences research innovation sector. 
Merck will provide $4 million in funding to the Institute for Research in 
Immunology and Cancer - Commercialization of Research (IRICoR) for future 
corridor projects developed in collaboration with two other Canadian Centres 
of Excellence for Commercialization and Research (CECRs) based inOntario and 
in British Columbia. 
IRICoR will work in conjunction with MaRS Innovation and the Centre for Drug 
Research and Development (CDRD) to identify, develop and commercialize 
technologies in healthcare. All three CECR institutions - identified as CECR 
in 2008 by the federal government - share a common objective: facilitating and 
accelerating the commercialization of research breakthroughs that will improve 
the quality of life of Canadians and others around the world. 
"The corridor initiatives we are funding today are part of our new approach to 
R&D which is about building collaborative research relationships. 
Private-public partnerships, in particular, will provide a fertile environment 
for innovation to grow and to quickly reach the commercialization stage in the 
best interest of patients," said Dr. Thomas Cannell, President and Managing 
Director, Merck Canada Inc. "This is an important milestone for the company as 
it is broadening its scope to include important research centers that are part 
of the Quebec - Ontario and Quebec - British Columbia corridors." 
"Merck Canada's investment in research and development in Quebec is excellent 
news, and its partnership with one of our public research flagships - 
Institute for Research in Immunology and Cancer - Commercialization of 
Research (IRICoR) - demonstrates the dynamic nature of our biopharmaceutical 
industry. Further, it is proof that our business environment is both 
competitive and well suited to this new industry model. It is for these 
reasons, and thanks to our highly skilled workforce, that Quebec remains the 
partner of choice in the development of pharmaceuticals," said Quebec Minister 
of Finance and the Economy, Mr. Nicolas Marceau. 
Ontario Minister of Research and Innovation, the Honourable Reza Moridi, said, 
"We commend Merck for this important investment that opens up exciting joint 
research and commercialization possibilities for the teams at MaRS Innovation 
in Ontario and IRICoR in Quebec. We support and seek collaborations such as 
this so that companies, institutions and governments can help foster economic 
growth and an improved quality of life for all." 
Bridging the commercialization gap between academic research and industry
"This important contribution further solidifies our position as the leading 
center for innovative drug discovery and medicinal chemistry in Quebec. The 
funds will allow us to continue to develop innovative therapies through our 
validated business model of working closely with leading pharmaceutical 
companies.This exciting partnership will leverage the unique expertise 
within IRICoR and its partners to capture more value from the world-class 
research being carried out in Quebec, Ontario, and British Columbia. This is 
the best way to rapidly bring the benefits of our cutting edge research to 
patients who are suffering from serious unmet medical needs," said Dr. Michel 
Bouvier, President and CEO of IRICoR. 
"MaRS Innovation joins Merck and IRICoR in welcoming this partnership and the 
life sciences research that it will support," said Dr. Raphael Hofstein, 
President and CEO of MaRS Innovation. "These funds will provide much-needed 
capital to help bridge the gap to successful commercialization for early-stage 
technologies, and will allow our scientists to demonstrate the depth of 
Canadian expertise when it comes to creating innovative life sciences 
"CDRD is delighted to be collaborating with Merck and IRICoR on selected 
projects of mutual interest. As a national drug development and 
commercialization centre, CDRD recognizes the critical importance of building 
partnerships such as this that bring together complementary resources from 
across the country," said Ms. Karimah Es Sabar, President and CEO of The 
Centre for Drug Research and Development (CDRD). "This is a unique occasion to 
further leverage CDRD's drug development platform to help Canada develop the 
most commercially-promising discoveries and maintain our competitive edge on 
the international scene," commented Ms. Es Sabar. 
This announcement marks the latest contribution by Merck in its 2010 
announcement to inject $100 million over five years in biopharmaceutical 
research and development (R&D) in Quebec. Today's announcement brings Merck's 
total contributions to date to approximately $65million. In late 2012, Merck 
announced a $13.5-million investment to fund basic and translational research 
at four prominent universities and hospital-affiliated Montréal research 
institutions, including the Research Institute of the McGill University Health 
Centre (RI-MUHC), the Université de Montréal Hospital Research Centre 
(CR-CHUM), the Montreal Heart Institute Research Centre (MHI) and Concordia 
University. Prior to that, in 2012, Merck invested $35 million in the Merck 
Lumira Biosciences Fund, as its primary investor and only pharmaceutical 
industry partner. The Fund, established by Merck in collaboration with Lumira 
Capital, Teralys Capital and other partners, provides investment capital to 
support early stage life science innovation in Quebec. 
Merck has invested $6.8 million in AmorChem, a fund launched in 2011 to 
increase the commercial potential of high quality academic research carried 
out in Quebec. In 2011, Merck also announced a $5 million investment over five 
years in the Quebec Consortium for Drug Discovery (CQDM). 
Note: All amounts expressed in this press release are in Canadian dollars 
unless otherwise noted. 
About Merck
Today's Merck is a global healthcare leader working to help the world be 
well. Merck is known as MSD outside the United States and Canada. Through 
our medicines, vaccines, biologic therapies, and consumer and animal products, 
we work with customers and operate in more than 140 countries to deliver 
innovative health solutions. We also demonstrate our commitment to increasing 
access to healthcare through far-reaching policies, programs and partnerships. 
For more information about our operations in Canada, visit 
About IRICoR
IRICoR, the Institute for Research in Immunology and Cancer - 
Commercialization of Research, is a non-profit organization whose mandate is 
to accelerate the discovery, development and commercialization of novel drugs 
in oncology, immunology and related indications that originate from 
Université de Montréal. IRICoR is Quebec's only fully-integrated drug 
discovery and commercialization center of its kind, with one of the largest 
academia-based medicinal chemistry groups in the country. IRICoR, as a Center 
of Excellence in Commercialization and Research, invests in highly innovative 
projects to rapidly transition them from academia to the market, while 
identifying the best development partners for these commercially-promising 
projects. For more information about IRICoR, please visit 
About MaRS Innovation
MaRS Innovation (MI) is the commercialization agent for the exceptional 
discovery pipeline from 16 leading Ontario academic institutions, and has 
raised over $65 million to commercialize their technologies. As a single-entry 
point to total member research activity of $1 billion in annual research and 
development, MI provides a gateway for investors and licensees who wish to 
access technology assets in Ontario. Supported by the Government of Canada 
through the Networks of Centres of Excellence, by the Government of Ontario 
through the Ontario Centres of Excellence, and by its member institutions, MI 
is a transformational partnership that turns research strengths into real 
commercial opportunities. MI's portfolio includes the most promising assets 
and advances commercialization into global markets through industry 
partnerships, licensing and company creation. For more information about MaRS 
Innovation, please visit 
About CDRD
The Centre for Drug Research and Development (CDRD) was established in 2007, 
and is Canada's fully-integrated, national drug development and 
commercialization centre, providing expertise and infrastructure to enable 
researchers from leading health research institutions to advance promising 
early-stage drug candidates. A Canadian Centre of Excellence for 
Commercialization and Research (CECR), CDRD's mandate is to de-risk 
discoveries stemming from publicly-funded health research and transform them 
into viable grant opportunities for the private sector — thus successfully 
bridging the commercialization gap between academia and industry, and 
translating research discoveries into new therapies for patients. For more 
information about CDRD please visit 
The news release is available at 
Forward Looking Statement
This news release includes "forward-looking statements" within the meaning of 
the safe harbor provisions of the United States Private Securities Litigation 
Reform Act of 1995. These statements are based upon the current beliefs and 
expectations of Merck's management and are subject to significant risks and 
uncertainties. If underlying assumptions prove inaccurate or risks or 
uncertainties materialize, actual results may differ materially from those set 
forth in the forward-looking statements. 
Risks and uncertainties include but are not limited to, general industry 
conditions and competition; general economic factors, including interest rate 
and currency exchange rate fluctuations; the impact of pharmaceutical industry 
regulation and health care legislation in the United States and 
internationally; global trends toward health care cost containment; 
technological advances, new products and patents attained by competitors; 
challenges inherent in new product development, including obtaining regulatory 
approval; Merck's ability to accurately predict future market conditions; 
manufacturing difficulties or delays; financial instability of international 
economies and sovereign risk; dependence on the effectiveness of Merck's 
patents and other protections for innovative products; and the exposure to 
litigation, including patent litigation, and/or regulatory actions. 
Merck undertakes no obligation to publicly update any forward-looking 
statement, whether as a result of new information, future events or otherwise. 
Additional factors that could cause results to differ materially from those 
described in the forward-looking statements can be found in Merck's 2012 
Annual Report on Form 10-K and the company's other filings with the Securities 
and Exchange Commission (SEC) available at the SEC's Internet site 
Media Contacts: 
Merck Ani Armenian 514-428-3395 
Quebec Stephanie Lyttle 514-843-2365 
Ontario Jennifer Lee 416-848-1383 
British Columbia Alexandra Presley 604-638-7459 
SOURCE: Merck 
To view this news release in HTML formatting, please use the following URL: 
CO: Merck
ST: Illinois
-0- Apr/22/2013 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.